APM
TVTX icon

Avidity Partners Management’s Travere Therapeutics TVTX Stock Holding History

Avidity Partners Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-827,010
Closed -$7.43M – 102
2023
Q4 		$7.43M Sell
827,010
-495,990
-37% -$3.61M 0.27% 63
2023
Q3 		$11.8M Buy
+1,323,000
New +$18.7M 0.48% 62
2020
Q3 		– Sell
-250,000
Closed -$5.1M – 86
2020
Q2 		$5.1M Buy
+250,000
New +$3.98M 0.33% 52

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Avidity Partners Management's TVTX Position: Q1 2024 in Review

Avidity Partners Management sold out of Travere Therapeutics (TVTX) in Q1 2024, closing a stake of 827,010 shares — an estimated $7.43M sold.

Avidity Partners Management first reported a position in TVTX in Q2 2020 and held it in 3 quarters. The position peaked at $11.8M in Q3 2023. 175 funds tracked by Wall St. Rank hold TVTX as of Q1 2024.

  • Avidity Partners Management reported no remaining Travere Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Avidity Partners Management sold 827,010 Travere Therapeutics shares in Q1 2024, an estimated $7.43M.
  • Avidity Partners Management first reported a position in Travere Therapeutics in Q2 2020 and held it in 3 quarters.
  • Avidity Partners Management's Travere Therapeutics position peaked at $11.8M in Q3 2023.
  • 175 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2024.

Based on Avidity Partners Management's 13F filing for Q1 2024, filed 15 May 2024.